sellModerate cluster of 410b5-1 plan
Lonnel Coats sold $1.9M of BPMC
director at Blueprint Medicines Corp. 19,824 shares at an average of $94.31, traded Nov 20, 2024, filed Nov 22, 2024.
Warning score
40Value
$1.9M
19,824 shares
Holdings after
2,242
-90% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +25Trade size$1.9M at market
- +20Share of holdings soldSold 90% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-24-027545, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 20, 2024 | MOption exercise Common Stock10b5-1 | +7,500 | $69.79 | $523k | 20,754 | Nov 22, 2024 |
| Nov 20, 2024 | MOption exercise Common Stock10b5-1 | +1,312 | $76.24 | $100k | 22,066 | Nov 22, 2024 |
| Nov 20, 2024 | SOpen-market sale Common Stock10b5-1 | -4,500 | $93.15 | $419k | 17,566 | Nov 22, 2024 |
| Nov 20, 2024 | SOpen-market sale Common Stock10b5-1 | -5,287 | $94.24 | $498k | 12,279 | Nov 22, 2024 |
| Nov 20, 2024 | SOpen-market sale Common Stock10b5-1 | -213 | $94.99 | $20k | 12,066 | Nov 22, 2024 |
| Nov 21, 2024 | SOpen-market sale Common Stock10b5-1 | -9,824 | $94.87 | $932k | 2,242 | Nov 22, 2024 |
| Nov 20, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,500 | $0.00 | $0 | 0 | Nov 22, 2024 |
| Nov 20, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,312 | $0.00 | $0 | 3,188 | Nov 22, 2024 |
Related signals
Other insiders at Blueprint Medicines Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 34Weak | Blueprint Medicines Corp | Percy H. Carter CHIEF SCIENTIFIC OFFICER | $135k 1,051 shares | -2% | |
| 39Weak | Blueprint Medicines Corp | Christina Rossi CHIEF OPERATING OFFICER | $150k 1,172 shares | -2% | |
| 38Weak | Blueprint Medicines Corp | Percy H. Carter CHIEF SCIENTIFIC OFFICER | $340k 2,659 shares | -5% | |
| 13Weak | Blueprint Medicines Corp | Jeffrey W. Albers director | $506k 5,000 shares | -3% | |
| 28Weak | Blueprint Medicines Corp | Christina Rossi CHIEF OPERATING OFFICER | $229k 2,274 shares | -3% | |
| 7Weak | Blueprint Medicines Corp | Ariel Hurley PRINCIPAL ACCOUNTING OFFICER | $284k 2,752 shares | -14% | |
| 21Weak | Blueprint Medicines Corp | Christina Rossi CHIEF OPERATING OFFICER | $231k 2,274 shares | -3% | |
| 25Weak | Blueprint Medicines Corp | Kate Haviland CHIEF EXECUTIVE OFFICER | $216k 2,498 shares | -1% | |
| 27Weak | Blueprint Medicines Corp | Christina Rossi CHIEF OPERATING OFFICER | $216k 2,274 shares | -3% | |
| 48Moderate | Blueprint Medicines Corp | Jeffrey W. Albers director | $512k 5,766 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.